ICB combined with chemoradiotherapy
CERVICAL CANCER
The standard care for patients with locally advanced cervical cancer is platinum-based concurrent chemoradiotherapy (CCRT) (Atezolizumab plus chemoradiotherapy. A phase I/Ib study of Atezolizumab prior to and concurrently given with chemoradiation (CRT) treatment (Arm A, where patients received one dose of Atezolizumab prior to CRT, and two doses during CRT) or concurrently given with CRT (Arm B, where patients received all three doses of Atezolizumab during CRT treatment) for women with node-positive, locally advanced cervical cancer (NRG-GY017) showed its preliminary results (Another phase I study (NCT01711515) also found that Ipilimumab following definitive chemoradiation can improve immune activation (